INTRODUCTION {#s1}
============

Colorectal cancer (CRC) is the third most common cancer and the third leading cause of cancer death in the United States \[[@R1]\]. Lymph node status is accepted as one of the most important prognostic factors in colorectal cancer \[[@R2]\]. The classic staging system for colorectal cancer is the tumor node metastasis (TNM) staging system, which stages lymph node involvement according to the absolute number of positive lymph nodes \[[@R2]\]. However, the TNM system does not take into account examined tumor-free lymph nodes. Therefore, lymph node ratio (LNR) has recently emerged as an important prognostic factor and a suitable staging method for node positive patients \[[@R3]--[@R5]\]. Nevertheless, it was still under controversy due to contradictory LNR consequences in the previous studies \[[@R6], [@R7]\]. A previous systematic review considered the evidence on LNR as a prognostic factor in the colorectal cancer \[[@R3]\]. However, the main research tool for this study is systemic review (only four series submitted for meta analysis). Since many new studies in the last years have investigated this topic and the last review date was around ten year ago, we aimed to clarify the prognostic role of NLR in patients with lymph node-positive colorectal cancer and conduct the first meta-analysis on this topic.

RESULTS {#s2}
=======

Eligible and characteristics of studies {#s2_1}
---------------------------------------

We identified 1598 potentially relevant articles from our search of the published literature. After removing duplications, scanning titles and abstracts and reading the full-text, 33 records \[[@R5], [@R7]--[@R38]\] encompassing a total of 81,331 (75,838 node positive) CRC patients were eligible for the present study based on our inclusion and exclusion criteria (Figure [1](#F1){ref-type="fig"}).

![A flow chart showed the selection of studies](oncotarget-07-72898-g001){#F1}

Demographic details and clinicopathologic characteristics of the included studies were summarized in Table [1](#T1){ref-type="table"} and Table [2](#T2){ref-type="table"}. The 75838 node positive colorectal cancer patients were all underwent curative surgery, and their median age ranged from 54 to 75 years. Of all the 33 studies, 16 were focused on colon cancer, 5 on rectal cancer, and 12 considered both the colon and the rectum. We also investigated the situation of lymph nodes harvested and the treatment strategy (Table [2](#T2){ref-type="table"}). The follow-up time ranged from 30.2 months to 86 months. The patients included in this study were diagnosed between 1991 and 2012.

###### Demographic details of all identified studies

  Study           Year   Sample   Patient age       Follow-up time        Country     Endpoint
  --------------- ------ -------- ----------------- --------------------- ----------- ----------
  Xue             2014   180      Median 54 years   Median 49 months      China       DFS
  Arda            2014   58       Median 60 years   Mean 4-year           Turkey      OS DFS
  Wang            2013   245      Median 61 years   Mean 6-year           China       OS
  Yen             2013   612      Median 67 years   Median 52 months      Taiwan      OS, DFS
  Tiago           2013   70       NA                Median 33 months      Brazil      DFS
  Zhu             2012   161      Mean 59.1 years   NA                    China       OS DFS
  Liang           2012   174      Mean 62 years     Median 62.5 months    China       OS DFS
  Kritsanasakul   2012   227      Mean 62.8 years   Median 86 months      Thailand    OS
  Jung            2012   78       Median 64 years   Median 46 months      Korea       OS DFS
  Shimomura       2011   266      Median 64 years   Median 42.4 months    Japan       DFS
  Hong            2011   130      Mean 64 years     Median 50 months      Korea       DFS
  Greenberg       2011   65       Mean 69 years     Mean 34 moths         Israel      OS,DFS
  Vaccaro         2009   362      Mean 67.4 years   Median 42 months      Argentina   OS DFS
  Galizia         2009   145      Median 66 years   Median 43 months      Italy       DFS
  Wang            2012   256      Mean 57.9         Median 37 months      China       OS
  Jing            2012   145      Median 66 years   Median 35.4 months    China       DFS
  Tong            2011   505      Median 61 years   Median 31.08 months   China       OS
  Shao            2011   282      NA                NA                    China       OS
  Jung            2010   514      Median 63 years   Median 48.5 months    Korea       OS DFS
  Wang            2008   24477    Mean 69.2 years   NA                    America     OS
  Peng            2008   318      Mean 55.3 years   Median 41 months      China       OS, DFS
  Derwinger       2008   265      Mean 72 years     Mean 3-year           Sweden      DFS
  Lee             2007   201      Median 59 years   Median 41 months      Korea       DFS
  Chin            2009   624      Mean 64.1 years   Mean 5-year           Taiwan      DFS
  Arslan          2014   440      Median 66 years   Median 30.6 months    Turkey      OS
  Kim             2009   232      NA                Median 53 months      Korea       OS
  Kobayashi       2011   452      NA                Median 5.3 years      Japan       OS
  Lykke           2013   3119     Median 72 years   Mean 5-year           Denmark     OS
  Moug            2014   1514     Mean 71.9 years   Median 5.3 years      Scotland    OS
  Thoma           2012   1908     Mean 68 years     Median 30.2 months    England     OS
  Parnaby         2015   921      Median 75 years   Median 52.8 months    England     OS,DFS
  Chen            2011   36712    Mean 69.6 years   NA                    America     OS
  Zhou            2015   180      Mean 59 years     Median 41.8 months    China       OS

"NA": not available; "OS": overall survival;"DFS": disease free survival.

###### Clinicopathologic characteristics of all studies

  Study           Stage     Location     Inclusion period   Treatment          No. of nodes (N+)
  --------------- --------- ------------ ------------------ ------------------ -------------------
  Xue             III       colorectum   2007--2012         R0 surgery         median 8,(2)
  Arda            III       colon        2006--2014         R0 surgery         NA
  Wang            III       colorectum   2000--2006         R0 surgery + AT    NA
  Yen             III       colorectum   2004--2008         R0 surgery + AT    median 18,(3)
  Tiago           III       colon        2005--2010         R0 surgery         median 18.5
  Zhu             III       rectum       2005--2010         R0 surgery         mean 13.4
  Liang           III       colorectum   2000--2003         R0 surgery         median 10,(3)
  Kritsanasakul   I--III    colorectum   1998--2007         R0 surgery + AT    median 10 (1.7)
  Jung            I--III    colon        1999--2007         R0 surgery + AT    median 7
  Shimomura       III       colorectum   1991--2008         R0 surgery + AT    median 14,(2)
  Hong            III       colon        2000--2006         R0 surgery + AT    median 28,(2)
  Greenberg       I--III    colorectum   2003--2009         R0 surgery + AT    median 16
  Vaccaro         III       colorectum   1980--2005         R0 surgery + AT    median 20,(2)
  Galizia         III       colon        1996--2007         R0 surgery + AT    median 15,(2)
  Wang            III       colon        1999--2008         R0 surgery + AT    mean 23.3(4.2)
  Jing            III       colon        1998--2008         R0 surgery + AT    mean 13.22(3.77)
  Tong            III       colorectum   1994--2007         R0 surgery         median 12,(2)
  Shao            II--III   colorectum   2000--2005         R0 surgery         mean 11.44(2.21)
  Jung            III       colorectum   1998--2007         R0 surgery + AT    median 14,(2)
  Wang            III       colon        1988--2003         curative surgery   NA
  Peng            III       rectum       1990--2004         R0 surgery + AT    mean 12(3.8)
  Derwinger       III       colon        1999--2003         R0 surgery + AT    median 11
  Lee             III       colon        1995--2001         R0 surgery + AT    median 17,(3)
  Chin            III       colon        1995--2003         R0 surgery + AT    NA
  Arslan          I--III    colon        2005--2011         R0 surgery         median 19
  Kim             III       rectum       1996--2006         R0 surgery + AT    median 17,(3)
  Kobayashi       III       rectum       1991--1998         R0 surgery + AT    median 37(2)
  Lykke           I--III    colon        2003--2008         R0 surgery         median 13(2)
  Moug            I--III    colon        2000--2004         R0 surgery + AT    median 11
  Thoma           III       colorectum   1997--2007         R0 surgery + AT    median 11(4)
  Parnaby         I--III    colon        2006--2012         R0 surgery + AT    median 16
  Chen            III       colon        1992--2004         R0 surgery         NA
  Zhou            II--III   rectum       2005--2010         R0 surgery + AT    median 11(4)

"AT": adjuvant treatment; "No. of nodes (N+)": total number of lymph nodes harvested (number of positive lymph nodes); "NA": not available.

All the HRs and their 95% CIs in the collected articles were listed in Table [3](#T3){ref-type="table"}. We also summarized the methodological quality details. Firstly, the cut-off value of the LNRs was quite different from each other and stratified methods were not consistent (Table [3](#T3){ref-type="table"}). Secondly, almost all of researchers used the multivariate statistical analysis models. Thirdly, most studies were retrospective study in design, while 5 articles were designed as the prospectively studies. Regarding the relationship between LNR and the clinicopathological characteristics of node positive colorectal cancer patients, no significant differences emerged for mean age and gender. Furthermore, the LNR was not associated with tumor location or T stage \[[@R15], [@R23], [@R39]\]. Higher LNR patients have, however, significant major proportion of a higher lymphovascular invasion and poor differentiation \[[@R15], [@R23], [@R39]\].

###### Summary table of HRs (95% CI) and HR calculation

  Study           HR (95%CI)              LNR cutoff value            LNR stratification   Statistical analysis   Study design
  --------------- ----------------------- --------------------------- -------------------- ---------------------- --------------
  **OS**                                                                                                          
  Arda            1.712 (0.982--2.984)    0.25                        NA                   MA                     R
  Wang            1.641 (1.099--2.450)    0.3                         Log rank analysis    MA                     R
  Yen             1.54 (1.05--2.22)       0.17                        Log rank analysis    MA                     R
  Zhu             3.655 (1.939--6.888)    0.43                        Mean                 MA                     R
  Liang           1.42 (1.13--1.76)       0.125, 0.26, 0.5            Quartiles            MA                     R
  Kritsanasakul   2.62 (1.79--3.85)       0.35, 0.69                  ROC curve analysis   MA                     R
  Jung            1.402 (1.265--4.564)    0, 0.01, 0.28               Median value         MA                     R
  Greenberg       12.2 (2.178--68.622)    0.13                        ROC curve analysis   MA                     R
  Vaccaro         2.3 (1.3--4.1)          0.25                        Quartiles            MA                     R
  Wang            1.754 (1.344--2.289)    0.11, 0.39                  Log rank analysis    MA                     P
  Tong            1.958 (1.652--2.321)    0.35, 0.69                  Log rank analysis    MA                     R
  Shao            1.263 (1.027--1.552)    0, 0.17, 0.41, 0.69         Literature data      MA                     R
  Jung            1.589 (1.106--2.284)    0.18                        Quartiles            MA                     R
  Wang            2.30 (2.083--2.545)     1/14, 0.25, 0.5             ROC curve analysis   MA                     SEER
  Peng            3.41 (1.63--7.13)       0.14, 0.49                  Literature data      MA                     R
  Arslan          2.197 (1.357--3.556)    0.05, 0.20                  NA                   UA                     P
  Kim             2.261(1.234--4.143)     0.1, 0.2, 0.4               Quartiles            MA                     R
  Kobayashi       2.114 (1.241--3.600)    0.04, 0.079, 0.15           Quartiles            MA                     R
  Lykke           1.560 (1.232--1.975)    0, 1/12, 1/4, 1/2           Literature data      MA                     P
  Moug            2.117 1.350--3.318)     0.05, 0.19, 0.39            Literature data      MA                     P
  Thoma           1.799 (1.132--2.859)    0, 0.11, 0.21, 0.36, 0.60   NA                   MA                     P
  Parnaby         2.464 (1.487--4.083)    0, 0.17, 0.41, 0.69         Literature data      MA                     L
  Chen            1.975 (1.519--2.568)    0.1, 0.24, 0.49, 0.99, 1    Log rank analysis    MA                     SEER
  Zhou            1.71 (1.1--2.65)        0, 0.19                     ROC curve analysis   MA                     R
  **DFS**                                                                                                         
  Xue             2.098 (1.050--4.192)    0.17                        ROC curve analysis   MA                     R
  Arda            1.736 (0.997--3.024)    0.25                        NA                   MA                     R
  Yen             1.53 (1.05--2.23)       0.17                        Log rank analysis    MA                     R
  Tiago           74.88 (1.55--3617.01)   0.15                        Literature data      MA                     R
  Zhu             2.775 (1.544--4.988)    0.43                        Mean                 MA                     R
  Liang           1.39 (1.15--1.69)       0.125, 0.26, 0.5            Quartiles            MA                     R
  Jung            3.073 (1.496--6.313)    0, 0.01, 0.28               Median value         MA                     R
  Shimomura       2.425 (1.497--3.922)    0.2                         ROC curve analysis   MA                     R
  Hong            5.868 (1.585--21.729)   0.1638                      Quartiles            MA                     R
  Greenberg       3.297 (0.875--12.427)   0.13                        ROC curve analysis   MA                     R
  Vaccaro         2.6 (1.5--4.8)          0.25                        Quartiles            MA                     R
  Galizia         5.56 (3.45--12.5)       0.1818                      ROC curve analysis   MA                     R
  Jing            11.75(3.20--43.12)      0.11, 0.20. 429             Quartiles            MA                     R
  Jung            1.596 (1.122--2.268)    0.18                        Quartiles            MA                     R
  Peng            3.82 (1.96--7.47)       0.14, 0.49                  Literature data      MA                     R
  Derwinger       10.6 (3.2--31.8)        0.12, 0.27, 0.4             Quartiles            MA                     R
  Lee             2.880 (1.950--4.253)    0.11, 0.24,                 Quartiles            MA                     R
  Chin            3.915 (1.249--12.269)   0.4, 0.7                    Log rank analysis    MA                     R
  Parnaby         2.877 (1.837--4.507)    0, 0.17, 0.41, 0.69         Literature data      MA                     R

Study design is described as prospective (P) or retrospective (R). SEER surveillance, epidemiology, and end results cancer registry; L location cancer registry.

NA, not available; OS, overall survival; DFS, disease -free survival;

ROC curve: receiver operating characteristic curve. LNR: lymph node ratio,

MA, multivariate statistical analysis models; UA, univariate statistical analysis models.

Meta-analysis results {#s2_2}
---------------------

As shown in Figure [2](#F2){ref-type="fig"}, a pooled HR and its 95%CI were calculated with a random model because of the heterogeneity test showed that statistically significant heterogeneity exists between the studies (for OS: *I*^2^ = 60.5%, *P* = 0.000; for DFS: *I*^2^ = 71.7%, *P* = 0.000). The result showed that elevated LNR may predict poor OS (*n* = 24) (the pooled HR was 1.91; 95% CI: 1.71--2.14) and DFS (the pooled HR was 2.75; 95% CI: 2.14--3.53). We next conducted subgroup analysis base on some important clinicopathological characteristics. The patients with higher LNR were all associated with decreased OS and DFS (Table [4](#T4){ref-type="table"}).

![Forest plots show the association between LNR and overall survival (A), disease free survival (B)](oncotarget-07-72898-g002){#F2}

###### Results of the meta-analysis

  Stratifications    No. of studies       Pooled Estimates   Model               Heterogeneity              
  ------------------ -------------------- ------------------ ------------------- --------------- --- ------ -------
  **OS**                                  24                 1.91 (1.71--2.14)   0.000           R   60.5   0.000
  **No. of nodes**   No. of nodes≥12      13                 1.97 (1.71--2.26)   0.000           F   35.2   0.101
                     No. of nodes\<12     8                  1.74 (1.40--2.17)   0.000           R   62     0.015
  **Location**       Colon                9                  2.11 (1.95--2.28)   0.000           F   35.1   0.137
                     rectum               5                  2.30 (1.79--2.96)   0.000           F   19.9   0.288
  **Treatment**      R0 surgery +AT       15                 1.96 (1.73--2.22)   0.000           F   8.8    0.355
                     R0 surgery           9                  1.83 (1.52--2.20)   0.000           R   81.3   0.000
  **Stage**          Stage III            15                 1.91 (1.71--2.14)   0.000           R   50.7   0.013
  **DFS**                                 19                 2.75 (2.14--3.53)   0.000           R   71.7   0.000
  **No. of nodes**   No. of nodes≥12      13                 2.87 (2.18--3.77)   0.000           F   48.8   0.062
                     No. of nodes \< 12   4                  2.69 (1.32--5.50)   0.000           R   81.5   0.001
  **Location**       Colon                9                  3.49 (2.47--4.93)   0.000           R   48.9   0.048
  **Treatment**      R0 surgery + AT      14                 3.06 (2.32--4.04)   0.000           R   63.2   0.001
                     R0 surgery           5                  1.91 (1.27--2.86)   0.002           R   59     0.045
  **Stage**          Stage III            16                 2.73 (2.06--3.61)   0.000           R   74.6   0.000

"OS": overall survival; "DFS": disease free survival; "AT": adjuvant treatment; "R": random effects model; "F": fixed effect model; "No. of nodes": total number of lymph nodes harvested.

Sensitivity analysis {#s2_3}
--------------------

Obvious heterogeneity was found in some analysis groups (Table [4](#T4){ref-type="table"}). The most possible sources of heterogeneity were analyzed by subgroup. But subgroup analysis could not completely explain the heterogeneity. Therefore, we performed sensitivity analysis (Figure [3](#F3){ref-type="fig"}). In the OS analysis for all, heterogeneity was significant (*I*^2^ = 60.5%, *P* = 0.000). When Shaos' study and Wangs' study were removed from analysis, the heterogeneity became insignificant (*P* = 0.109 and *I*^2^ = 28.1%). As to DFS analysis for all (*I*^2^ = 71.7%, *P* = 0.000), we found that Liangs', Yen\'s and Jungs' study were responsible for the heterogeneity of DFS analysis group (*P* = 0.091 and *I*^2^ = 33.9%). After we excluded the publications with statistically significant heterogeneity and repeated the analysis, the summary estimates for higher LNR did not change statistically significantly (OS for all: the pooled HR was 1.85; 95% CI: 1.72--2.00; DFS for all: the pooled HR was 3.01; 95% CI: 2.55--3.55).

![Sensitivity analysis of the association between LNR and overall survival (A), disease free survival (B)](oncotarget-07-72898-g003){#F3}

Publication bias {#s2_4}
----------------

Funnel plots and Egger\'s test were conducted to evaluate the publication bias of included studies. No obvious visual asymmetry was observed in funnel plots (Figure [4](#F4){ref-type="fig"}) for OS, and the *P* values of the Egger\'s test were 0.800. However, statistically significant publication bias was found in the studies of DFS (Egger\'s test *P* value = 0.000). The funnel plot for the studies of DFS showed an asymmetrical distribution of the studies (Figure [4](#F4){ref-type="fig"}). Therefore we used the trim-and-fill method (Figure [5](#F5){ref-type="fig"}). As a consequence, there were 6 potential missing studies, and after these 6 potentially unpublished studies were filled, the recalculated pooled HR was 2.24 (95% CI: 1.75--2.88, *p* \< 0.00001) in the random effects model. That indicated a positive outcome even though publication bias still exists.

![Funnel plot of the association between LNR and overall survival (A), disease free survival (B)](oncotarget-07-72898-g004){#F4}

![Trim and fill funnel plot for the source of publication bias](oncotarget-07-72898-g005){#F5}

DISCUSSION {#s3}
==========

The prognosis of patients with colorectal cancer was largely related to the lymph node status, which helps in tumor staging and clinical decision. According to the current TNM staging system proposed by the AJCC/ UICC \[[@R2]\], N categories were determined by the absolute number of involved lymph nodes (N1, one to three; N2, four or more). Although this categorization has been proven to predict long term outcomes and well accepted \[[@R40]\], it is noteworthy that the TNM system does not take into account some important features of lymph node metastasis. In fact, many features of lymph node such as the number of non metastasis lymph nodes and the extra-nodal extension of nodal metastasis retrieved from the resection specimen which has been shown to have a prognostic significance in CRC \[[@R41], [@R42]\]. Furthermore, LNR can be considered as a hallmark of aggressiveness, since it was associated with a higher percentage of lymphovascular invasion and poor tumor differentiation \[[@R15], [@R23], [@R39]\].

In last decades, many researchers suggested that LNR could be a prognostic factor in different types of malignancies especially most of the gastrointestinal cancers \[[@R43]--[@R46]\]. This meta-analysis confirmed that higher LNR is statistically significantly associated with a poor survival of colorectal cancer. The results were similar when we subgroup the patients according to some important clinicopathological characteristics. Furthermore, we carried out a sensitivity analysis, which suggested the stability of our meta-analysis. We encountered evidence of publication bias in our main analysis, but our results remained unchanged after we adjusted for this. In current meta-analysis, we excepted the studies which included patients underwent neo-adjuvant treatment because it has reported that the total number of retrieved lymph nodes and positive lymph nodes may decrease after preoperative chemoradiation \[[@R47], [@R48]\].

Our results have demonstrated the significant weight of LNR in the prognosis of CRC. It is recommended to include LNR as a prognostic parameter in future colorectal staging system. It is important to note that the extent of dissection would influence the LNR. Generally, a more extensive surgical dissection of the specimen results in a higher number of positive nodes. And a ratio based on a small number of lymph nodes has a larger standard error, which could affect the reliability of the LNR in those patients who had less extensive dissection \[[@R49], [@R50]\]. So, adequate lymph nodes retrieved from the operative specimen was still important.

Our study had some advantages. First, this is the first complete meta-analysis identify the prognostic role of LNR in CRC. Second, this meta-analysis included plenty of primary studies (33 papers) and patients (75,838 node positive patients). The statistical power is well enough for our results. However, this study also had several limitations which are largely reflected by those within the primary studies. First, data about other co-morbidities (like cardiovascular diseases) were not reported, but it is known that they play an important prognostic role also in patients with cancer. Second, The cut-off value for defining LNR in each included study is quite different, which may have contributed to heterogeneity. Regarding which cutoff value will be the most reliable for predicting the prognostic values of colorectal cancer patients, the available evidence could not achieve an agreement. This needs a large cohort study or an individual patient data meta-analysis which could stratify and evaluate different LNRs on the CRC prognosis and find out the minute differences in prognostic outcomes. Finally, we also encountered some heterogeneity but were able to investigate sources of this within subgroup analysis and sensitive analysis.

In conclusion, this meta-analysis indicated that higher LNR can be used as a predictor of poor survival and assists in the choice of adjuvant treatment in the clinical setting in patients with CRC. We proposed that the LNR could be a prognostic parameter in future colorectal staging system.

MATERIALS AND METHODS {#s4}
=====================

Search strategy and selection criteria {#s4_1}
--------------------------------------

We systematically searched PubMed, Embase and the Cochrane library (<http://www.cochrane.org>) using the "lymph node ratio", "LNR";"lymph positive node ratio", "lymph metastatic node ratio" Medical Subject Heading (MeSH) terms "Colorectal Neoplasms" and the individual corresponding free terms such as "colorectal cancer", "colon cancer", "rectal cancer" "colorectal adenocarcinoma", "colon adenocarcinoma", "rectal adenocarcinoma", "colorectal carcinoma", "colon carcinoma", "rectal carcinoma", "colorectal tumor", "colon tumor", "rectal tumor". No language or other restrictions were applied. The last search was updated on 28 November, 2015. In addition, we reviewed references in the retrieved articles to search for additional relevant studies.

Studies eligible in the meta-analysis fulfilled the following inclusion criteria: (1) the patients were pathologically diagnosed as CRC with node-positive who underwent curative surgery (R0 resection);(2) the outcome of interest was overall survival (OS) and disease free survival (DFS);(3) hazard ratio (HR) and 95% confidence intervals (CI) were sufficiently reported. Exclusion criteria were defined as follows: (1) the patients have distant metastasis (TNM stage IV) or received neoadjuvant chemotherapy; (2) Letters, reviews, expert opinions, and case reports.

Data extraction {#s4_2}
---------------

The following information were extracted from each selected papers if available: first author, year of publication, country of the study population, number of patients, number of nodes examined, type of study, cut-off value for the LNR and definition of the strata, follow-up years, the location and the TNM stage of the tumor, and HRs with 95% CI. Two investigators reviewed and extracted information independently and checked by the other authors. Discrepancies were settled by consensus.

Statistical analysis {#s4_3}
--------------------

The statistical analyses were carried out using STATA 12.0 (STATA Corporation, College Station, TX, USA). The HRs with 95% CI from each study were extracted to generate a pooled HR. Heterogeneity among studies was checked using the chi-squared test and I^2^ statistics. If the *P value* \< 0.05 and/or I^2^ \> 50% indicating statistical significance, a random effects model was used to obtain summary HRs. Otherwise, a fixed effect model was utilized. In addition, we conducted a sensitivity analysis to investigate the potential sources of heterogeneity and assess the strength of our findings by sequentially excluding one study. Furthermore, factors contributed to heterogeneities were also analyzed by stratifying the subjects according to the tumor location. Publication bias among the studies was investigated by using Begg\'s funnel plot and the Egger\'s test.
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